Millennium Pharmaceuticals Limited

Biogen Ma Inc.

Sunesis Pharmaceuticals, Inc.

The Institute for Pharmaceutical Discovery, LLC

Other

The Institutes for Pharmaceutical Discovery LLC

Alinea Pharmaceuticals, Inc.

The Institute for Dibetes Discovery LLC

Biogen Idec Ma Inc.

John Howard Jones

Zhili Xin

Michael C Van Zandt

David Gunn

Michael Lee Jones

Gnanasambandam Kumaravel

Alexey Alexandrovich Lugovskoy

Hiroko Tanaka

Bing Guan

Hairuo Peng

Noel Aaron Powell

Brian Raimundo

Jeffrey Vessels

Jennifer Cossrow

Thomas Wynn

Felix Gonzalez Lopez De Turiso

Martin Himmelbauer

William M Jones

Michael A Dechantsreiter

Weirong Chen

Michael Brandon Jones

Benjamin Lane

Adam Littke

Lloyd Franklin

Edward Yin-Shiang Lin

Brian Stuart Lucas

Alexey V Ishchenko

Istvan J Enyedy

Kurt D Van Vloten

TeYu Chen

Andrew George Capacci

Lloyd P Dewey

Lioyd Franklin

Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R, R, Rand n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

ASK1 inhibiting agents

Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R, R, R, Rand n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

NRF2 activator

The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, L, L, Cy, and Cyare as defined as set forth in the specification.

Substituted pyrimidines for inhibiting Raf kinase activity

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Compounds useful as Raf kinase inhibitors

Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.

Substituted indolealkanoic acids

The present invention provides compounds useful as inhibitors of protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Heterocyclic compounds useful as RAF kinase inhibitors

Aryl and heteroaryl substituted indolealkanoic acids

Growing community of inventors

Framingham, MA, United States of America

John Howard Jones